Core Points - A class action securities lawsuit has been filed against DexCom, Inc. for alleged securities fraud affecting investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - These design changes allegedly made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The enhancements to the G7's reliability, accuracy, and functionality were reportedly overstated by the defendants [2] - The true scope and severity of the issues with the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Insights - Aurora Cannabis Inc. has announced a distribution partnership with Leafio to enhance access to medical cannabis for patients in Australia [1][2] - The partnership aims to provide educational resources for healthcare professionals and improve patient outcomes through a reliable supply chain [2][5] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across multiple regions including Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of brands, including MedReleaf, CanniMed, and Whistler Medical Marijuana Co., and is focused on high-quality cannabis products [3] Partnership Details - The agreement allows Leafio to distribute Aurora's medical cannabis products through its nationwide supply chain, which services over 4,000 pharmacies in Australia [2][5] - The partnership is expected to enhance research, product innovation, and clinician education, ultimately benefiting the medical cannabis industry in the region [2][6] Market Impact - This collaboration is positioned to significantly improve access to consistent, high-quality medical cannabis for Australian patients [2][6] - The partnership reflects Aurora's commitment to expanding its leadership in the Australian market and enhancing patient access to medical cannabis [2][6]

Accessibility StatementSkip Navigation MORRISTOWN, N.J., Nov. 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY on December 3, 2025, at 12 ...

Group 1 - Solventum will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 2, 2025, at approximately 10:00 a.m. EST [1] - A live and archived replay of the fireside chat will be available on the company's investor website [1] Group 2 - Solventum is focused on enabling better healthcare through innovative solutions at the intersection of health, material, and data science [2] - The company aims to improve patients' lives and empower healthcare professionals [2] Group 3 - Solventum announced a $1 billion share repurchase program approved by its Board of Directors [3] - The company has entered into a definitive agreement to acquire Acera Surgical, a privately held bioscience company [4]

Core Insights - Roche Pharmaceuticals has chosen to extend its partnership with Veeva Systems by adopting Veeva Vault CRM, which is expected to enhance customer engagement through AI capabilities [1][2]. Company Overview - Veeva Systems provides industry cloud solutions for life sciences, offering software, data, and business consulting services to over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [3]. Partnership Details - The partnership extension will implement Vault CRM across Roche's global Pharma organization, aiming to create more personalized interactions and provide insights to better support healthcare professionals and patients [2]. - Veeva AI, which includes various agentic AI features, will be integrated into the Vault CRM platform, with specific agents like Free Text Agent, Voice Agent, Pre-call Agent, and Media Agent expected to be available in December 2025 [2].

Core Viewpoint - Innovent Biologics has been successfully included as a constituent stock of the Hang Seng Index (HSI), marking a significant milestone in its development and recognition in the international capital market [1][4][5]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing high-quality medicines for major diseases such as cancer, cardiovascular and metabolic disorders, autoimmune diseases, and ophthalmology [3][6]. - The company has launched 16 products and has a diversified drug pipeline that includes monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and small-molecule drugs [3][6]. Market Recognition - The inclusion in the HSI and other indices like the Hang Seng China Enterprises Index (HSCEI) and the Hang Seng ESG Enhanced Index highlights the strong recognition of Innovent's value as an innovative biopharmaceutical company [1][4]. - This milestone reflects the Hong Kong stock market's preference for high-quality Chinese innovative biopharmaceutical enterprises [4]. Strategic Implications - Innovent's inclusion in the HSI is expected to broaden its investor base, enhance international visibility, and provide solid capital support for ongoing investments in innovative R&D and global business expansion [5]. - The company aims to continue its mission of developing affordable, high-quality biopharmaceuticals for patients worldwide, thereby creating long-term value for investors [5][6].

Core Insights - Alkami Technology, Inc. is under investigation for potential securities fraud and unlawful business practices [1] - The company reported third-quarter 2025 financial results, with GAAP earnings per share of -$0.14, missing estimates by $0.02, and revenue of $113 million, missing estimates by $0.48 million [2] - Following the earnings report, Alkami's stock price dropped by $1.70, or 7.73%, closing at $20.29 per share [2] Company Financial Performance - For Q3 2025, Alkami reported a GAAP earnings per share of -$0.14, which was below the consensus estimate by $0.02 [2] - The revenue for the same quarter was $113 million, falling short of consensus estimates by $0.48 million [2] Stock Market Reaction - The announcement of the financial results led to a decline in Alkami's stock price by $1.70, representing a 7.73% decrease [2]

Group 1 - Indivior PLC will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with CEO Joe Ciaffoni and CFO Ryan Preblick hosting meetings and a fireside discussion [1] - The fireside discussion will be publicly available via a live webcast [1] - Indivior focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease [1] Group 2 - Indivior presented new real-world evidence at the AMCP Nexus 2025 conference, highlighting the clinical and economic benefits of adherence to monthly injectable buprenorphine [2] - The company reported its third-quarter financial results for 2025 and raised its full-year financial guidance [3]

Core Insights - Theravance Biopharma, Inc. will participate in two investor conferences in December 2025, focusing on healthcare and rare diseases [1][2] Group 1: Upcoming Events - The company will present at the 8th Annual Evercore Healthcare Conference on December 4, 2025, in a fireside chat format from 8:20 to 8:40 AM ET [1] - Theravance will also participate in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, with a panel discussion scheduled from 2:15 to 2:45 PM ET [1] - One-on-one meetings will be available for interested investors during both events [1] Group 2: Company Overview - Theravance Biopharma focuses on delivering impactful medicines, leveraging decades of expertise [3] - The company has developed YUPELRI (revefenacin), an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD) [3] - Ampreloxetine, a late-stage investigational drug for neurogenic orthostatic hypotension in patients with Multiple System Atrophy, is being developed as a potential first-in-class therapy [3]

Core Insights - BioArctic AB's partner Eisai will present new findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference, focusing on long-term treatment benefits, safety, and subcutaneous administration [1][5][9] Presentation Highlights - Key presentations will include data on long-term treatment effects and estimated time savings over 10 years, as well as safety and benefits of subcutaneous dosing for initiation [1][5] - Real-world clinical practice insights will be shared, including findings from the US ALZ-NET registry [1][5] Poster Presentations - A poster session will cover various studies, including baseline characteristics and safety findings from the ALZ-NET registry [3] - Additional topics include enrollment patterns in preclinical trials, stability and improvement in early Alzheimer's disease, and patient acceptability of the autoinjector for subcutaneous delivery [4] Continued Treatment Analysis - New analyses will be presented on the benefits of continued lecanemab therapy and estimated time savings based on Phase 3 clinical data [5][7] - A late-breaking symposium will discuss the potential benefits of subcutaneous initiation dosing and related pharmacokinetic findings [5] Mechanism and Clinical Outcomes - Presentations will review the effects of lecanemab on soluble amyloid-beta protofibrils and clinical outcomes from subcutaneous administration [6][7] - A societal cost comparison between subcutaneous and intravenous lecanemab will also be discussed [7] Collaboration and Development - Lecanemab is a result of a long-term collaboration between BioArctic and Eisai, with BioArctic holding commercialization rights in the Nordic region [7][11] - The drug is approved in 51 countries and under review in 9, with a focus on subcutaneous dosing in the U.S. [9][11]